StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities researchers at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Sunday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 0.6 %

NYSE:BTX opened at $6.29 on Friday. The firm’s fifty day simple moving average is $3.99 and its 200 day simple moving average is $1.88. Brooklyn ImmunoTherapeutics has a twelve month low of $6.06 and a twelve month high of $8.31. The firm has a market capitalization of $370.02 million, a price-to-earnings ratio of -2.77 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.